 |
| The most obvious impact on orders in Newport's second quarter of 2012 (versus Q1 2012) was felt from the life and health sciences market - although that was largely due to a huge order for ultrafast lasers that was booked in Q1. Newport's cost reduction measures relate more to a slowdown in government support for research and what CEO Robert Phillippy described as "political gridlock" in the US that could hit defense spending at the end of the year. Source: Newport Corporation. |
| © 2024 SPIE Europe |
|
